ISI Provides Color on Biogen Idec

ISI provided color on Biogen Idec BIIB. In a research report published today, ISI commented on the company's product Tysabri. In the report, ISI states, “Earlier today, BIIB released their July 2011 Tysabri update on the number of cases of PML for patients. Interestingly, they noted that 1 patient at the time of PML diagnosis tested negative for anti-JCV virus. We've confirmed with the company that this is the first time that a patient diagnosed with PML has also tested negative for anti-JCV antibodies. Importantly, the company mentioned to us that the patient was tested 24 hours after plasma exchange (PLEX) therapy.“ On Thursday, BIIB lost 2.01% of its value to finish the day at $103.19. Its shares continued to shed value in today's pre-market trading, falling 1.93% to trade around $101.19.